Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a/b Single Arm Open Label Study to Evaluate the Safety and Efficacy of Intracystic Administration of TARA-002 in Participants Between 6 Months to Less Than 18 Years of Age for the Treatment of Macrocystic and Mixed Cystic Lymphatic Malformations

Next Previous
X
Search
Trial Profile

A Phase 2a/b Single Arm Open Label Study to Evaluate the Safety and Efficacy of Intracystic Administration of TARA-002 in Participants Between 6 Months to Less Than 18 Years of Age for the Treatment of Macrocystic and Mixed Cystic Lymphatic Malformations

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Picibanil (Primary)
  • Indications Lymphatic disorders
  • Focus Therapeutic Use
  • Acronyms STARBORN-1
  • Sponsors Protara Therapeutics

    • Most Recent Events

    • 05 Mar 2025 According to a Protara Therapeutics media release, interim results form this trial expected by the end of the first half of 2025.
    • 09 Sep 2024 Results presented in a Protara Therapeutics Media Release.
    • 09 Sep 2024 According to a Protara Therapeutics media release, enrollment in additional cohorts underway with initial results expected in 1H 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top